Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 3,500 shares, an increase of 169.2% from the May 15th total of 1,300 shares. Based on an average daily trading volume, of 4,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PHAR. Oppenheimer lifted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th.

Pharming Group Stock Down 6.0%

NASDAQ PHAR opened at $10.87 on Friday. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average is $9.63 and its two-hundred day moving average is $9.16. The company has a market capitalization of $739.57 million, a price-to-earnings ratio of -41.81 and a beta of 0.02. Pharming Group has a 1-year low of $6.65 and a 1-year high of $12.61.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The company had revenue of $79.09 million during the quarter, compared to analysts’ expectations of $67.74 million. Equities analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.